The modulation of the immunosuppressive microenvironment with the inhibition of IDO1 and JQ1, a drug decreasing the expression of PD-L1 by tumor cells, improved the immunotherapy treatment of GBM in mice [101]. The gene discussed is CD274; the disease is glioblastoma.